Sodium-dependent
glucose cotransporters (SGLTs) have attracted considerable attention as new targets for
type 2 diabetes mellitus. In the kidney, SGLT2 is the major
glucose uptake transporter in the proximal tubules, and inhibition of SGLT2 in the proximal tubules shows renoprotective effects. On the other hand, SGLT1 plays a role in
glucose absorption from the gastrointestinal tract, and the relationship between SGLT1 inhibition in the gut and renal function remains unclear. Here, we examined the effect of
SGL5213, a novel and potent intestinal SGLT1 inhibitor, in a
renal failure (RF) model.
SGL5213 improved renal function and reduced gut-derived
uremic toxins (phenyl
sulfate and
trimethylamine-N-oxide) in an
adenine-induced RF model. Histological analysis revealed that
SGL5213 ameliorated renal
fibrosis and
inflammation.
SGL5213 also reduced gut
inflammation and
fibrosis in the ileum, which is a primary target of
SGL5213. Examination of the gut microbiota community revealed that the Firmicutes/Bacteroidetes ratio, which suggests gut
dysbiosis, was increased in RF and
SGL5213 rebalanced the ratio by increasing Bacteroidetes and reducing Firmicutes. At the genus level, Allobaculum (a major component of Erysipelotrichaceae) was significantly increased in the RF group, and this increase was canceled by
SGL5213. We also measured the effect of
SGL5213 on bacterial
phenol-producing
enzymes that catalyze
tyrosine into
phenol, following the reduction of phenyl
sulfate, which is a novel marker and a therapeutic target for
diabetic kidney disease DKD. We found that the
enzyme inhibition was less potent, suggesting that the change in the microbial community and the reduction of
uremic toxins may be related to the renoprotective effect of
SGL5213. Because
SGL5213 is a low-absorbable SGLT1 inhibitor, these data suggest that the gastrointestinal inhibition of SGLT1 is also a target for
chronic kidney diseases.